According to Future Market Insights, the vutrisiran market sales is expected to develop at a compound annual growth rate (CAGR) of 12% between 2023 and 2033. By 2033, it is projected that the global Vutrisiran market would be valued at US$ 2087 million. The market is growing because vutrisiran gives patients with hereditary transthyretin-mediated amyloidosis (hATTR) hope and a new therapeutic option.
the launch of Vutrisiran, patients with hATTR have a new, promising treatment option that addresses the underlying cause of the disease. Vutrisiran is a small interfering RNA (siRNA) molecule that works by inhibiting the production of abnormal TTR protein, which is responsible for the buildup of amyloid deposits. By reducing the production of abnormal TTR, Vutrisiran slows down the progression of the disease and improves the quality of life for patients.
Get a Sample Copy of the Report:
https://www.futuremarketinsights.com/reports/sample/rep-gb-16993
The launch of Vutrisiran is a significant milestone in the field of hATTR treatment. The medication has shown promising results in clinical trials, demonstrating its safety and efficacy in reducing TTR protein levels and improving clinical outcomes in patients. In a Phase III clinical trial, Vutrisiran was found to reduce TTR protein levels by 85% on average, and nearly all patients experienced a significant improvement in their neurological symptoms.
The launch of Vutrisiran is a game-changer for the hATTR market, as it offers a new and effective treatment option for patients with this devastating disease. The medication has the potential to improve the lives of thousands of individuals living with hATTR and their families by slowing down the progression of the disease and improving clinical outcomes.
Key Takeaways:
- The global Vutrisiran market is expected to grow with a 12% CAGR during 2023 to 2033.
- Hospital pharmacies are expected to hold 46% of the market share in 2023 for Vutrisiran market.
- North America is expected to possess 45% market share for Vutrisiran market in 2023.
- Europe vutrisiran market size is expected to possess 41% market share in 2023.
“The safety and efficacy of Vutrisiran have been demonstrated in clinical trials. Owing to this, key players are investing in the development of vutrisiran,” states an FMI analyst
Request Report Methodology:https://www.futuremarketinsights.com/request-report-methodology/rep-gb-16993
Competitive Landscape::
Key players in the vutrisiran market are Alnylam Pharmaceuticals, Inc., Orphalan, AstraZeneca, Vivet Therapeutics, Pfizer, Ultragenyx Pharmaceutical, Valeant Pharmaceuticals International, Inc., Noblepharma Co., Ltd., Merck & Co., Inc., Teva Pharmaceuticals
- Alnylam Pharmaceuticals has a strong pipeline of other RNAi-based therapies in development for a range of diseases. The success of Vutrisiran has helped to drive investor confidence in the company and increase funding for its other pipeline drugs, which could result in new treatment options for patients.
- Alnylam Pharmaceuticals has established patient access programs to ensure that patients who need Vutrisiran have access to the drug. These programs provide financial assistance, support services, and other resources to help patients access and afford Vutrisiran.
Key Segments :
Drug Class:
- Antisense Oligonucleotides
- Nucleic Acids
- Nucleotide
- Nucleosides
Route of Administration:
- Injectable
- Parenteral
- Subcutaneous
Distribution Channel:
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Unlock Tailored Insights: Customize Your Report for Maximum Impact:
https://www.futuremarketinsights.com/customization-available/rep-gb-16993
Author By:
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
